NeoVax + CDX-301 and Nivolumab in Advanced Melanoma
Status:
Not yet recruiting
Trial end date:
2027-01-31
Target enrollment:
Participant gender:
Summary
This research study is studying the drugs called NeoVax (a new type of personalized
neoantigen vaccine) in combination with CDX-301 and Nivolumab as a possible treatment for
melanoma.
The names of the study drugs involved in this study are:
- Personalized Neoantigen peptides (which combined with poly-ICLC make the vaccine NeoVax)
- Poly-ICLC (Hiltonol)
- CDX-301
- Nivolumab (Opdivo)